Plain-English translation of NCT05640271 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Sickle Cell Disease research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing whether , a medication that reduces inflammation in the body, can help people with sickle cell disease recover more quickly when they develop acute chest syndrome—a serious complication that makes it hard to breathe. Researchers want to understand whether giving this medication early in the crisis makes a difference compared to waiting, or compared to standard care.
Acute chest syndrome is one of the most dangerous complications of sickle cell disease and can cause lasting lung damage or death. Right now, there are limited treatment options beyond supportive care, so researchers are looking for new ways to stop the inflammation and help people recover faster and better.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive either the medication or a placebo (salt water) as your first dose when you are diagnosed with acute chest syndrome, and then the opposite dose 48 hours later. Researchers will monitor your oxygen levels, collect blood tests, and ask you about how you are feeling throughout your hospital stay. The study compares how quickly people recover and how well they breathe depending on whether they received the medication early or later.
AI-generated summary from trial data · Jul 19, 2026 · Not medical advice
United States